Dabrafenib
Drug Details
- Description
- Dabrafenib is a kinase inhibitor targeting BRAF V600E mutation, used primarily for treating melanoma and certain types of thyroid cancer. It interferes with cellular signaling pathways to inhibit tumor cell proliferation.
- Alternative Names
- Dabrafenib
- Key Genes
- Dabrafenib targets the BRAF gene, specifically the BRAF V600E mutation.
- Drug Use
- Dabrafenib is used to treat certain types of melanoma, non-small cell lung cancer, and thyroid cancer, specifically those with a BRAF V600E mutation.
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report